沃森生物13价肺炎疫苗落户马来西亚

Group 1 - Watson Bio's subsidiary, Yuxi Watson Biotechnology Co., Ltd., has signed an agreement with Pharmaniaga Lifescience Sdn. Bhd. for the distribution and local production of the PCV-13 vaccine in Malaysia [1] - The agreement aims to facilitate technology transfer, local production, and commercialization of the PCV-13 vaccine, addressing the stable annual demand of approximately 1.5 million doses in Malaysia [1] - This collaboration is part of Watson Bio's strategy to expand its "Chinese medicine" overseas, marking the sixth localization project for the PCV-13 vaccine after similar initiatives in Morocco, Indonesia, Egypt, Mexico, and Bangladesh [2] Group 2 - Pharmaniaga Berhad is the largest listed integrated healthcare company in Malaysia, with its subsidiary having obtained EU GMP certification in 2013 and becoming the first Malaysian pharmaceutical company with human vaccine filling capabilities in 2021 [2] - Watson Bio, established in 2001, is the first company in China and the second globally to independently develop and successfully market the PCV-13 vaccine, maintaining a leading market share in China since 2021 [3] - RevonBio FZ-LLC, based in Dubai, supports Chinese biopharmaceutical companies in commercializing their products in emerging markets [4]